RecruitingNCT07531511

SLC6A1-NDD Prospective Longitudinal Natural History Study

Sponsor

UCB Biopharma SRL

Enrollment

60 participants

Start Date

Jul 21, 2026

Study Type

OBSERVATIONAL

Conditions

SLC6A1 Neurodevelopmental Disorder (NDD)Developmental and Epileptic Encephalopathies (DEE)

Summary

The overall objective of this prospective longitudinal natural history study is to collect clinical data to characterize and evaluate the natural course of SLC6A1-NDD and assess the feasibility of certain assessments for the purpose of conducting future clinical studies in patients with this disease.

Eligibility

Max Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with developmental and epileptic encephalopathies (dee) and slc6a1 neurodevelopmental disorder (ndd). The study is currently recruiting participants at 3 locations. People eligible for this study include up to age 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(3)

Gtep01 50614

New York, New York, United States

Gtep01 40131

Strasbourg, France

Gtep01 40870

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07531511